Treatment of Recurrent Clostridium Difficile Infection With RBX7455
NCT ID: NCT02981316
Last Updated: 2020-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2016-11-30
2020-07-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RBX7455 Group A
4 days of 4 capsules twice daily RBX7455 for 10 subjects.
RBX7455
Microbiota capsule(s) given twice daily in the morning, and in the evening.
RBX7455 Group B
2 days of 4 capsules twice daily RBX7455 for 10 subjects.
RBX7455
Microbiota capsule(s) given twice daily in the morning, and in the evening.
RBX7455 Group C
2 days of 2 capsules twice daily RBX7455 for 10 subjects.
RBX7455
Microbiota capsule(s) given twice daily in the morning, and in the evening.
RBX7455 Group D
2 days of 1 capsule twice daily RBX7455 for 10 subjects.
RBX7455
Microbiota capsule(s) given twice daily in the morning, and in the evening.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RBX7455
Microbiota capsule(s) given twice daily in the morning, and in the evening.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Medical record documentation of recurrent CDI, defined as at least one recurrence after a primary episode and has completed at least two rounds of standard-of-care oral antibiotic therapy. Study subjects will have their diarrhea resolved, i.e., would be having less than 3 watery bowel movements at the time of study enrollment for 48 hours or more.
3. A positive stool test for the presence of C. difficile within 30 days prior to enrollment and standard C. difficile treatment.
4. Willing and able to swallow capsules.
5. Agrees to abstain from non-dietary probiotics for the duration of the study.
6. Agrees to abstain from vancomycin, metronidazole, fidaxomicin, rifaximin, nitazoxanide and IVIG for the duration of the study unless prescribed to treat recurrent CDI.
7. Agrees to stop proton pump inhibitors or H2 blocker medications.
8. Agrees to practice a form of effective contraception during study participation.
9. Has a negative urine pregnancy test at the time of enrollment (females of child-bearing potential only).
10. Willing and able to provide informed consent and HIPAA authorization.
11. Willing and able to complete the required Subject Diary.
12. Willing and able to meet all study requirements, including attending all assessment visits and phone calls.
Exclusion Criteria
2. Requires continuous antibiotic therapy for a condition other than CDI.
3. Previous fecal transplant.
4. Previous treatment with RBX2660.
5. Diagnosis of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn's disease, or microscopic colitis.
6. Diagnosis of irritable bowel syndrome (IBS) as determined by Rome III criteria.
7. History of chronic diarrhea.
8. History of celiac disease.
9. Disease symptoms caused by a confirmed intestinal pathogen other than C. difficile.
10. Unable to stop proton pump inhibitors or H2 blocker medications.
11. Colostomy.
12. Intra-abdominal surgery within the last 60 days.
13. Evidence of active, severe colitis.
14. History of short gut syndrome.
15. Requires the regular use of medications to manage bowel hypermotility.
16. Planned therapy in the next 3 months that may cause diarrhea (e.g., chemotherapy).
17. Planned surgery requiring perioperative antibiotics within 3 months of study enrollment.
18. Life expectancy of \< 6 months.
19. Compromised immune system (e.g., HIV infection; AIDS-defining diagnosis or CD4 \<200/mm3; inherited/primary immune disorders; immunodeficient or immunosuppressed due to a medical condition or medication; current or recent (\< 90 days) treatment with chemotherapy; or current or recent (\< 90 days) treatment with immunosuppressant medications.
20. Taking systemic steroids (≥ 20 mg a day or prednisone-equivalent) or is expected to be on steroids after enrollment through 8 weeks after completing the assigned study treatment.
21. An absolute neutrophil count of \<1000 cells/µL.
22. Known or suspected current (\< 90 days) illicit drug use. Note: marijuana use is allowed.
23. Pregnant, breastfeeding, or intends to become pregnant during study participation.
24. Participating in a clinical trial of another investigational product (drug, device or other) and has not completed the required follow-up period.
25. Subject, in the opinion of the investigator, for whatever reason, should be excluded from the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rebiotix Inc.
INDUSTRY
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sahil Khanna
M.B.B.S.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sahil Khanna
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Khanna S, Pardi DS, Jones C, Shannon WD, Gonzalez C, Blount K. RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections. Clin Infect Dis. 2021 Oct 5;73(7):e1613-e1620. doi: 10.1093/cid/ciaa1430.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-008828
Identifier Type: -
Identifier Source: org_study_id